{"title": "COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds", "author": null, "url": null, "hostname": null, "description": null, "sitename": "2022 Archive - COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds", "date": "2017-01-13", "cleaned_text": "December 20, 2022 | [January Payne](mailto:january.payne@som.umaryland.edu) Contact January Payne Director of Public Relations University of Maryland School of Medicine Office of Public Affairs & Communications c: 443-203-8183 e: january.payne@som.umaryland.edu t: @januarypayne Related stories Wednesday, February 16, 2022 [Study Shows New Drug Combination More Effective Against SARS-CoV-2](https://www.medschool.umaryland.edu/news/2022/Study-Shows-New-Drug-Combination-More-Effective-Against-SARS-CoV-2.html) Researchers at the University of Maryland School of Medicine (UMSOM) and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19. The researchers showed that combining the experimental drug brequinar with either of the two drugs already approved by the U.S. Food and Drug Administration for emergency use, remdesivir or molnupiravir, inhibited growth of the SARS-CoV-2 virus in human lung cells and in mice. Their findings suggest that these drugs are more potent when used in combination than individually. Wednesday, January 26, 2022 [Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of \"Mix-and-Match\" COVID-19 Vaccine Booster Dosing](https://www.medschool.umaryland.edu/news/2022/Trial-Co-led-by-University-of-Maryland-School-of-Medicine-Scientist-Confirms-Safety-of-Mix-and-Match-COVID-19-Vaccine-Booster-Dosing.html) A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person's primary vaccine(s). Thursday, December 16, 2021 [Novavax COVID-19 Vaccine Found to be Safe and Effective in Phase 3 Trial Conducted by UM School of Medicine Researchers](https://www.medschool.umaryland.edu/news/2021/Novavax-COVID-19-Vaccine-Found-to-be-Safe-and-Effective-in-Phase-3-Trial-Conducted-by-UM-School-of-Medicine-Researchers.html) An investigational COVID-19 vaccine made by Novavax was found to be 90 percent effective at preventing COVID-19 illness, according to results from a Phase 3 clinical trial published today in the New England Journal of Medicine. The University of Maryland School of Medicine's (UMSOM) Center for Vaccine Development and Global Health served as one of the trial sites, and Karen Kotloff, MD, Professor of Pediatrics at UMSOM, served as Co-Chair for the trial protocol. Tuesday, December 14, 2021 [UM School of Medicine's Office of Public Affairs and Communications Honored with 2021 PRSA 'Best In Maryland' Award ](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicines-Office-of-Public-Affairs-and-Communications-Honored-with-2021-PRSA-Best-In-Maryland-Award-.html) The University of Maryland School of Medicine (UMSOM)'s Office of Public Affairs & Communications received the Public Relations Society of America (PRSA) 2021 \"Best in Maryland Award,\" the PRSA's highest honor, for its COVID-19 Communications program. The award was given at the PRSA Maryland Gala, held on December 9, 2021. Wednesday, September 08, 2021 [UM School of Medicine Reaching Underserved Communities Through Grass Roots Efforts to Increase COVID-19 Vaccination Rates](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Reaching-Underserved-Communities-Through-Grass-Roots-Efforts-to-Increase-COVID-19-Vaccination-Rates.html) In an effort to increase COVID-19 vaccination rates among children and families, and ultimately help bring the pandemic under control, the Department of Family & Community Medicine (DFCM) and the Department of Psychiatry at the University of Maryland School of Medicine (UMSOM) are partnering with key community and faith-based groups in Baltimore city to reach the most vulnerable and underserved communities. This partnership will also extend across Maryland, Delaware, Virginia, and West Virginia. Wednesday, July 07, 2021 [UM School of Medicine Researchers Develop Two Rapid Tests for COVID-19 Using Innovative Techniques ](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Researchers-Develop-Two-Rapid-Tests-for-COVID-19-Using-Innovative-Techniques-.html) Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold-standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods. Wednesday, June 09, 2021 [Global Study of Microbes in 60 Cities Finds Each Has Unique Fingerprint of Viruses and Bacteria](https://www.medschool.umaryland.edu/news/2021/Global-Study-of-Microbes-in-60-Cities-Finds-Each-Has-Unique-Fingerprint-of-Viruses-and-Bacteria.html) Each city has its own unique microbiome, a \"fingerprint\" of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell. Tuesday, March 16, 2021 [New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel](https://www.medschool.umaryland.edu/news/2021/New-Study-Finds-Healthcare-Settings-Do-Not-Pose-Added-Risk-Factor-for-Covid-19-Infection-Spread-Among-US-Healthcare-Personnel.html) Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities. Friday, February 05, 2021 [UM School of Medicine Researchers Demonstrate Strong Immune Response for New COVID-19 Vaccine in Pre-Clinical Tests](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Researchers-Demonstrate-Strong-Immune-Response-for-New-COVID-19-Vaccine-in-Pre-Clinical-Tests.html) Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax. The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the U.S. with a Phase 3 trial that recently launched at the UMSOM's Center for Vaccine Development and Global Health. Thursday, January 21, 2021 [UM School of Medicine Hosted Media Availability for Ensuring Trust in COVID-19 Vaccine Event](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Hosted-Media-Availability-for-Ensuring-Trust-in-COVID-19-Vaccine-Event.html) On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and \"America's Doctor,\" Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research. Tuesday, January 05, 2021 [Dr. Kathleen Neuzil, World-renowned Leader in Moderna Vaccine](https://www.medschool.umaryland.edu/news/2020/Dr-Kathleen-Neuzil-World-renowned-Leader-in-Vaccine-Research-Receives-Moderna-Vaccine.html) Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine's (UMSOM)'s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December. Tuesday, January 05, 2021 [University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate](https://www.medschool.umaryland.edu/news/2020/University-of-Maryland-School-of-Medicine-Begins-Phase-3-Trial-of-Novavax-COVID-19-Vaccine-Candidate.html) Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD. Thursday, November 19, 2020 [Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine](https://www.medschool.umaryland.edu/news/2020/Promising-Results-Seen-in-PfizerBioNTech-COVID-19-Vaccine-After-Phase-1-Trial-by-University-of-Maryland-School-of-Medicine.html) Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19. Friday, November 13, 2020 [UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-and-School-of-Pharmacy-Researchers-Identify-Promising-New-Compounds-to-Potentially-Treat-Novel-Coronaviruses.html) Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal. Tuesday, June 16, 2020 [UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Receive-Federal-Funding-to-Rapidly-Test-New-Treatments-for-COVID-19.html) Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government's Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort. Tuesday, June 02, 2020 [UM School of Medicine's Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicines-Institute-of-Human-Virology-Awarded-Grants-to-Strengthen-COVID-19-Response-in-Sub-Saharan-Africa.html) The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine's Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique. Monday, June 01, 2020 [In A COVID-19 World, Another Threat to the Health of Our Children](https://www.medschool.umaryland.edu/news/2020/In-A-COVID-19-World-Another-Threat-to-the-Health-of-Our-Children.html) In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations. Thursday, May 28, 2020 [UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Develop-Experimental-Rapid-COVID-19-Test-Using-Innovative-Nanoparticle-Technique.html) Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society's nanotechnology journal ACS Nano. Thursday, May 21, 2020 [UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Begins-First-Innovative-Trial-of-Experimental-Stem-Cell-Therapy-to-Reduce-Deaths-in-Sickest-COVID-19-Patients.html) Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC. Tuesday, May 05, 2020 [UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-is-First-in-US-to-Test-Unique-RNA-Vaccine-Candidate-for-COVID-19.html) In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine. Thursday, April 23, 2020 [UM School of Medicine Researchers Test Remdesivir as Potential Therapy for COVID-19 Patients](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Test-Remdesivir-as-Potential-Therapy-for-COVID-19-Patients.html) Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Friday, April 10, 2020 [University of Maryland School of Medicine Launches New Large Scale COVID-19 Testing Initiative](https://www.medschool.umaryland.edu/news/2020/University-of-Maryland-School-of-Medicine-Launches-New-Large-Scale-COVID-19-Testing-Initiative.html) University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland. Tuesday, December 10, 2019 [UMSOM Researchers to Test Vaccine Designed to Protect Against Serious Illness from Contaminated Food and Water](https://www.medschool.umaryland.edu/news/2019/UMSOM-Researchers-to-Test-Vaccine-Designed-to-Protect-Against-Serious-Illness-from-Contaminated-Food-and-Water.html) Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC), and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens. Friday, September 20, 2019 [UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research](https://www.medschool.umaryland.edu/news/2019/UM-School-of-Medicines-Center-for-Vaccine-Development-and-Global-Health-Receives-NIH-Contract-of-up-to-More-than-200-Million-for-Influenza-Research.html) Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised. Monday, August 19, 2019 [UM School of Medicine Researcher Warns of Need for Malaria Drug to Treat Severe Cases in U.S.](https://www.medschool.umaryland.edu/news/2019/UM-School-of-Medicine-Researcher-Warns-of-Need-for-Malaria-Drug-to-Treat-Severe-Cases-in-US.html) Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM). Tuesday, August 13, 2019 [UM School of Medicine Researchers Begin Phase 1 Clinical Trial of Vaccine Against Mosquito-Borne Diseases](https://www.medschool.umaryland.edu/news/2019/UM-School-of-Medicine-Researchers-Begin-Phase-1-Clinical-Trial-of-Vaccine-Against-Mosquito-Borne-Diseases.html) Mosquito-borne diseases including malaria, dengue and yellow fever, have a severe impact resulting in millions of deaths worldwide, hitting the world's most vulnerable populations the hardest. Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental vaccine that is designed to protect against a series of these diseases. Friday, November 02, 2018 [UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel](https://www.medschool.umaryland.edu/news/2018/UMSOM-Global-Health-Expert-Named-to-Prestigious-World-Health-Organization-Immunization-Panel.html) Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization. Wednesday, June 06, 2018 [UMSOM Researchers Find that Silent Carriers of Malaria are Unlikely to Develop the Disease](https://www.medschool.umaryland.edu/news/2018/UMSOM-Researchers-Find-that-Silent-Carriers-of-Malaria-are-Unlikely-to-Develop-the-Disease.html) In regions where malaria illness is widespread, it is common to find many individuals who are infected with malaria parasites (Plasmodium falciparum), but without symptoms. New research conducted by the University of Maryland School of Medicine (UMSOM) shows that treating these silent malaria cases could help stop the spread of malaria to others. Tuesday, May 15, 2018 [Tackling Malaria Transmission in Sub-Saharan Africa](https://www.medschool.umaryland.edu/news/2018/Tackling-Malaria-Transmission-in-Sub-Saharan-Africa.html) Two malaria experts in the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine wrote a commentary published in the June Issue of The Lancet Global Health discussing the prevalence of malaria in school-age children in sub-Saharan Africa. Miriam Laufer, MD, Associate Professor of Pediatrics and Associate Director for Malaria Research CVD, and Lauren Cohee, MD, Instructor, Pediatrics, noted that often malaria infection is more common in school-age children than younger children and adults. Friday, January 13, 2017 [Scientists Identify Vaccination as the Most Cost-Effective Strategy to Sharply Reduce Rabies Deaths in India](https://www.medschool.umaryland.edu/news/2017/Scientists-Identify-Vaccination-as-the-Most-Cost-Effective-Strategy-to-Sharply-Reduce-Rabies-Deaths-in-India.html) Every year in India, 20,000 people are estimated to die from rabies. Most of the victims are children. Nearly all of the deaths occur after victims are bitten by rabid dogs. For years, experts have debated the best strategy to reduce this burden. "}